Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease
about
Serologic markers in inflammatory bowel disease: tools for better diagnosis and disease stratificationAnti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel diseaseNovel Anti-Glycan Antibodies Related to Inflammatory Bowel Disease Diagnosis and PhenotypeNovel biomarkers of fibrosis in Crohn's diseaseAntibody markers in the diagnosis of inflammatory bowel diseaseDepletion of Saccharomyces cerevisiae in psoriasis patients, restored by Dimethylfumarate therapy (DMF).Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease.Emerging prognostic markers to determine Crohn's disease natural history and improve management strategies: a review of recent literature.Serum antibodies and anthropometric data at diagnosis in pediatric Crohn's disease.Does evidence exist to include dietary therapy in the treatment of Crohn's disease?Assessing inflammatory bowel disease-associated antibodies in Caucasian and First Nations cohorts.Current and future role of biomarkers in Crohn's disease risk assessment and treatment.Differential response to microbial antigens by age of diagnosis in patients with Crohn's diseaseNOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn's disease in African AmericansClinical implications of inflammatory bowel disease genetics on phenotype.Distinct IFNG methylation in a subset of ulcerative colitis patients based on reactivity to microbial antigens.Immunogenetic phenotypes in inflammatory bowel disease.IBD serological panels: facts and perspectives.Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease.Partial overlap of anti-mycobacterial, and anti-Saccharomyces cerevisiae mannan antibodies in Crohn's diseaseNon-invasive investigation in patients with inflammatory joint disease.Serologic antiglycan antibodies in inflammatory bowel disease.Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease.Serological antibodies in inflammatory bowel disease: a systematic review.Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysisHave genomic discoveries in inflammatory bowel disease translated into clinical progress?Circulating antibodies against bacterial wall products: are there arguments for early immunosuppression?Serological markers of inflammatory bowel disease.Towards personalized care in IBD.Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy.The value of serum antibodies in differentiating inflammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient.Ethnic and socio-cultural specificities in Tunisia have no impact on the prevalence of anti-Saccharomyces cerevisiae antibodies in Crohn's disease patients, their relatives or associated clinical factors.Incidence of Bowel Surgery and Associated Risk Factors in Pediatric-Onset Crohn's Disease.Serologic antibodies in relation to outcome in postoperative Crohn's disease.Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study.Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort.Flare factor: are there any triggering factors associated with onset of clinical symptoms or disease relapse?Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: a meta-analysis.Predictive value of serologic markers in a population-based Norwegian cohort with inflammatory bowel disease.Interaction between seroreactivity to microbial antigens and genetics in Crohn's disease: is there a role for defensins?
P2860
Q22241487-80D7ACF2-18AB-4B8D-A5C6-568E5A72F770Q22242053-BB1126BC-ADE9-48DF-B733-68E20BE7F207Q22251117-F521E7C8-BC32-407C-A588-7812372B8822Q26738287-CAEE68F9-1F35-47A9-B8AA-975E5E856F91Q26774452-B697ABBF-B75E-418A-AAB0-4CAFFEF2250DQ33653077-729EA812-078F-42FD-AF64-B4189AF69631Q33894195-61F5740C-F8FB-44BD-B9D0-C2E6B205E726Q33916303-3B190F41-C284-4251-A523-93A4C5B9F1E4Q34072574-177AD4C2-FCDA-44CD-8FFC-013F1286B724Q34618308-CF07E2BE-0023-47E8-9D98-85CC01680C50Q35045292-4BBF5905-0944-409C-BA77-699EBA50F064Q35095265-D5FAED72-E00C-4B08-9BBB-C29D98845E89Q35743193-15FB3FEC-EDCE-4DF6-A946-9C31BBB16B18Q35919095-4784DDEB-5716-4656-88F7-ABC262FAC1A9Q36021426-14C34650-BBF2-4E92-9300-F93DAE17CB3AQ36104271-D72BA791-D789-4EFB-A92F-2F6CFB7E20B3Q36506455-5356FCCB-7C67-4874-A8DE-1CBA1AEA70B1Q36884782-15574FBB-53B3-4843-9C6C-54D6A0ABBC58Q37064590-11E0920E-9BB2-427A-8A49-C8D3D5B677EDQ37284803-70F68CC9-257F-4150-B8B1-6921AE7454D9Q37495751-A6EA8D96-7F12-446E-8816-5C625B4922ACQ37829904-D6C7E87A-9345-4536-BB67-349B050AC0D9Q37937183-191B7D1D-A83D-4403-BC47-9B5FD29BBB18Q37954231-534C9A7F-1916-4F2B-A46A-61BFA5314E53Q37980405-E0822AEA-E06E-4C27-AB7F-0AA6D8229C0FQ37981121-76DA3D0A-B016-41A5-84FE-A2835F605633Q38072225-24BAE901-7FF5-41E6-AD64-BAF5FCD960D6Q38086247-BE6A9AB0-9466-433C-A817-56011A6F6909Q38171924-D712B147-E75D-4FF1-B08A-1A2F91C57216Q38492052-E8B2AC64-E6B2-4697-9712-196327A71B7DQ38702824-89BFAE0F-CF9D-4776-BA73-6D0D216DE34DQ39040664-2F4C691C-831F-458D-9E2C-F07BA3082290Q39276665-1FC4CDC4-9A6A-48BB-AE8A-C0AB1902370DQ40409129-A55E607D-1435-48DF-BC9F-2C6CEEF0D065Q44207530-C7C04006-2163-4DEC-B47D-E7F4DB2F774FQ44551200-E945846F-D993-42A7-86A8-6AFA6DE18CD1Q44895109-A1117176-5E06-424C-AF75-352D11661428Q47661706-CD07B4F9-006E-4B23-BA97-0294EE5BB93AQ51674064-DDC2D6B5-0283-4722-AD6C-A30B036F4992Q51707293-8BAE4F86-215F-475D-BEC1-B640AF4B98AC
P2860
Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Anti-Saccharomyces cerevisiae ...... rly surgery in Crohn's disease
@ast
Anti-Saccharomyces cerevisiae ...... rly surgery in Crohn's disease
@en
type
label
Anti-Saccharomyces cerevisiae ...... rly surgery in Crohn's disease
@ast
Anti-Saccharomyces cerevisiae ...... rly surgery in Crohn's disease
@en
prefLabel
Anti-Saccharomyces cerevisiae ...... rly surgery in Crohn's disease
@ast
Anti-Saccharomyces cerevisiae ...... rly surgery in Crohn's disease
@en
P2093
P2860
P921
P356
P1433
P1476
Anti-Saccharomyces cerevisiae ...... rly surgery in Crohn's disease
@en
P2093
D G Forcione
J B Kisiel
P2860
P304
P356
10.1136/GUT.2003.030734
P407
P577
2004-08-01T00:00:00Z